Michael Davidson/LinkedIn
Nov 23, 2025, 14:48
Michael Davidson: Why LDL Alone Isn’t Enough for CV Risk Reduction
Michael Davidson, CEO of NewAmsterdam Pharma, posted on LinkedIn:
”Today’s standard lipid-lowering therapies focus almost exclusively on LDL-C reduction. Yet across large-scale studies, only 20–35% of patients taking them are meeting their risk-based LDL-C goals, highlighting the need for additional therapies.
Additionally, to maximize cardiovascular risk reduction, we need to address additional factors like lipoprotein(a), small LDL particles, and ApoB.
Learn how we can broaden the approach to reducing cardiovascular risk.”
Read more here.
Stay updated wth Hemostasis Today.
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026